Tradewinds Capital Management’s Sage Therapeutics SAGE Stock Holding History

Tradewinds Capital Management’s Portfolio SAGE Stock Details SAGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-137	Closed	-$10K	–	728
2019 Q4	$10K	Hold	137	–	–	﹤0.01%	423
2019 Q3	$19K	Hold	137	–	–	0.01%	284
2019 Q2	$25K	Hold	137	–	–	0.01%	249
2019 Q1	$22K	Hold	137	–	–	0.01%	271
2018 Q4	$13K	Hold	137	–	–	0.01%	338
2018 Q3	$19K	Hold	137	–	–	0.01%	326
2018 Q2	$21K	Hold	137	–	–	0.01%	309
2018 Q1	$22K	Hold	137	–	–	0.01%	289
2017 Q4	$23K	Hold	137	–	–	0.01%	291
2017 Q3	$9K	Hold	137	–	–	﹤0.01%	412
2017 Q2	$11K	Hold	137	–	–	0.01%	384
2017 Q1	$10K	Buy	+137	New	+$8.03K	0.01%	398

Other funds holding SAGE

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

Tradewinds Capital Management's SAGE Position: Q1 2020 in Review

Tradewinds Capital Management sold out of Sage Therapeutics (SAGE) in Q1 2020, closing a stake of 137 shares — an estimated $10K sold.

Tradewinds Capital Management first reported a position in SAGE in Q1 2017 and held it in 12 quarters. The position peaked at $25K in Q2 2019. 230 funds tracked by Wall St. Rank hold SAGE as of Q1 2020.

Tradewinds Capital Management reported no remaining Sage Therapeutics position as of Q1 2020 after selling out during the quarter.
Tradewinds Capital Management sold 137 Sage Therapeutics shares in Q1 2020, an estimated $10K.
Tradewinds Capital Management first reported a position in Sage Therapeutics in Q1 2017 and held it in 12 quarters.
Tradewinds Capital Management's Sage Therapeutics position peaked at $25K in Q2 2019.
230 funds tracked by Wall St. Rank held Sage Therapeutics as of Q1 2020.

Based on Tradewinds Capital Management's 13F filing for Q1 2020, filed 11 May 2020.